Efficacy and Efficacy-influencing Factors of Stem Cell Transplantation on Patients with Parkinson's Disease: a Systematic Review and Meta-analysis

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Apr 29

PMID 38682036

Authors

Jianli Zhao

Kang Qu

Shanshan Jia

Rong Yang

Ziting Cui

Jiajia Li

Peng Yu

Ming Dong

Affiliations

Soon will be listed here.

Abstract

Background: Cell transplants as a treatment for Parkinson's disease have been studied for decades, and stem cells may be the most promising cell sources for this treatment. We aimed to investigate whether stem cell transplantation contributes to the cure for Parkinson's disease and the factors that may influence the efficacy for this therapy.

Methods: PubMed, Embase, Cochrane Library, Web of Science, SinoMed, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and ChinaInfo were thoroughly searched to find controlled trials or randomized controlled trials performing stem cell transplantation in patients with Parkinson's disease. The pooled effects were analyzed to evaluate the weighted mean difference (WMD) with 95% confidence intervals.

Results: Nine articles were identified including 129 individuals. Stem cell transplantation was an effective treatment for Parkinson's disease (WMD = -14.86; 95% CI: -16.62 to -13.10; < 0.00001), with neural stem cells, umbilical cord mesenchymal stem cells (UCMSCs), and bone marrow mesenchymal stem cells (BMMSCs) being effective cell sources for transplantation. Stem cell transplantation can be effective for at least 12 months, but its long-term effectiveness remains unknown due to the limited studies monitoring patients for more than 1 year, not to mention decades.

Conclusion: Data from controlled trials suggest that stem cell transplantation as a therapy for Parkinson's disease can be effective for at least 12 months. The factors that may influence its curative effect are time after transplantation and stem cell types.

Systematic Review Registration: (Registration ID: CRD42022353145).

References

Takahashi J . Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. Prog Brain Res. 2017; 230:213-226. DOI: 10.1016/bs.pbr.2016.11.004. View

Kordower J, Brundin P . Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another?. Neuropsychopharmacology. 2008; 34(1):254. DOI: 10.1038/npp.2008.161. View

Li J, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O . Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord. 2010; 25(8):1091-6. DOI: 10.1002/mds.23012. View

Barker R . Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nat Med. 2019; 25(7):1045-1053. DOI: 10.1038/s41591-019-0507-2. View

Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S . Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999; 122 ( Pt 6):1121-32. DOI: 10.1093/brain/122.6.1121. View

Armstrong M, Okun M . Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020; 323(6):548-560. DOI: 10.1001/jama.2019.22360. View

Yin F, Tian Z, Liu S, Zhao Q, Wang R, Shen L . Transplantation of human retinal pigment epithelium cells in the treatment for Parkinson disease. CNS Neurosci Ther. 2012; 18(12):1012-20. PMC: 6493491. DOI: 10.1111/cns.12025. View

Kurowska Z, Englund E, Widner H, Lindvall O, Li J, Brundin P . Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J Parkinsons Dis. 2013; 1(1):83-92. DOI: 10.3233/JPD-2011-11004. View

Kordower J, Rosenstein J, Collier T, Burke M, Chen E, Li J . Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol. 1996; 370(2):203-30. DOI: 10.1002/(SICI)1096-9861(19960624)370:2<203::AID-CNE6>3.0.CO;2-6. View

10.

Schiess M, Suescun J, Doursout M, Adams C, Green C, Saltarrelli J . Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease. Mov Disord. 2021; 36(8):1825-1834. PMC: 8451899. DOI: 10.1002/mds.28582. View

11.

Parmar M, Grealish S, Henchcliffe C . The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020; 21(2):103-115. DOI: 10.1038/s41583-019-0257-7. View

12.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Sivandzade F, Cucullo L . Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int J Mol Sci. 2021; 22(4). PMC: 7926761. DOI: 10.3390/ijms22042153. View

15.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

16.

Andrzejewska A, Dabrowska S, Lukomska B, Janowski M . Mesenchymal Stem Cells for Neurological Disorders. Adv Sci (Weinh). 2021; 8(7):2002944. PMC: 8024997. DOI: 10.1002/advs.202002944. View

17.

Freed C, Greene P, Breeze R, Tsai W, DuMouchel W, Kao R . Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001; 344(10):710-9. DOI: 10.1056/NEJM200103083441002. View

18.

Tansey M, Wallings R, Houser M, Herrick M, Keating C, Joers V . Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022; 22(11):657-673. PMC: 8895080. DOI: 10.1038/s41577-022-00684-6. View

19.

Sonntag K, Song B, Lee N, Jung J, Cha Y, Leblanc P . Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. Prog Neurobiol. 2018; 168:1-20. PMC: 6077089. DOI: 10.1016/j.pneurobio.2018.04.005. View

20.

Madrazo I, Kopyov O, Avila-Rodriguez M, Ostrosky F, Carrasco H, Kopyov A . Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery. Cell Transplant. 2018; 28(3):269-285. PMC: 6425108. DOI: 10.1177/0963689718820271. View